ERBB2 and breast cancer: In one study, a triple therapy of GM-CSF autologous BC vaccine, trastuzumab, and cyclophosphamide for HER2+ BC conferred a 6-month clinical benefit rate of 55% [57], which was hypothesized to work via a DC-driven augmentation of CD8+ CTLs [113].